Display options
Cite
Sayın R, Aslan M, Kucukoglu ME, et al. Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine. 2013;47(1):146-51doi: 10.1007/s12020-013-0136-3.
Sayın, R., Aslan, M., Kucukoglu, M. E., Luleci, A., Atmaca, M., Esen, R., & Demir, H. (2014). Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine, 47(1), 146-51. https://doi.org/10.1007/s12020-013-0136-3
Sayın, Refah, et al. "Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy." Endocrine vol. 47,1 (2014): 146-51. doi: https://doi.org/10.1007/s12020-013-0136-3
Sayın R, Aslan M, Kucukoglu ME, Luleci A, Atmaca M, Esen R, Demir H. Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine. 2014 Sep;47(1):146-51. doi: 10.1007/s12020-013-0136-3. Epub 2013 Dec 18. PMID: 24347244.
Copy Download .nbib Format: NLM
Share it on

Endocrine. 2014 Sep;47(1):146-51. doi: 10.1007/s12020-013-0136-3. Epub 2013 Dec 18.

Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy.

Endocrine

Refah Sayın, Mehmet Aslan, Mehmet Emin Kucukoglu, Arda Luleci, Murat Atmaca, Ramazan Esen, Halit Demir

Affiliations

  1. Department of Neurology, Medical Faculty, Yuzuncu Yil University, Van, Turkey.

PMID: 24347244 DOI: 10.1007/s12020-013-0136-3

Abstract

Previous studies have suggested that prolidase and nitric oxide (NO) regulate many processes, such as collagen synthesis and matrix remodeling. Oxidative stress plays an important role in the development of microvascular complications in diabetic patients. Data on serum prolidase activity in patients with diabetes mellitus or diabetic neuropathy (DN) are limited and conflicting. The aim of this study was to measure serum prolidase activity, NO, total antioxidant status (TAS), and malondialdehyde (MDA) levels in patients with DN. Forty-five patients with DN and 40 healthy controls were enrolled. Serum prolidase activity, TAS, MDA, and NO levels were determined. Serum MDA and NO levels were significantly higher in DN patients than controls (p = 0.002, p = 0.001, respectively), while prolidase activity and TAS levels were lower (p = 0.003, p = 0.001, respectively). Prolidase activity was negatively correlated with NO and MDA (r = -0.911, p < 0.001; r = -0.905, p < 0.001, respectively), while positively correlated with TAS (r = 0.981, p < 0.001) in DN patients. The current study is the first showing the decreased serum prolidase enzyme activity. Our results suggest that decreased collagen turnover may occur in DN patients, who have increased oxidative stress and increased NO levels. Decreased prolidase activity seems to be associated with increased NO levels and oxidative stress along with decreased antioxidant levels in DN. Therefore, decreased prolidase activity may play a role in pathogenesis of DN. Prospective clinical studies are necessary to confirm these findings.

References

  1. Antioxid Redox Signal. 2009 Mar;11(3):425-38 - PubMed
  2. Am J Hum Genet. 1989 May;44(5):731-40 - PubMed
  3. Diabetes. 1991 Apr;40(4):405-12 - PubMed
  4. Arterioscler Thromb Vasc Biol. 1996 Jul;16(7):831-42 - PubMed
  5. Clin Biochem. 1985 Aug;18(4):220-3 - PubMed
  6. Clin Biochem. 2007 Jan;40(1-2):37-40 - PubMed
  7. Neuro Endocrinol Lett. 2010;31(2):261-4 - PubMed
  8. Ren Fail. 2006;28(4):271-4 - PubMed
  9. Diabetologia. 2001 Nov;44(11):1973-88 - PubMed
  10. J Anat. 2009 Feb;214(2):219-25 - PubMed
  11. Clinics (Sao Paulo). 2010;65(12):1311-4 - PubMed
  12. Clin Biochem. 1999 Aug;32(6):423-7 - PubMed
  13. Am J Obstet Gynecol. 1979 Oct 1;135(3):372-6 - PubMed
  14. Lancet Neurol. 2012 Jun;11(6):521-34 - PubMed
  15. Clin Biochem. 2004 Apr;37(4):277-85 - PubMed
  16. Muscle Nerve. 1988 Jul;11(7):661-7 - PubMed
  17. Diabetes Care. 1997 Jul;20(7):1183-97 - PubMed
  18. J Clin Invest. 1990 Feb;85(2):380-4 - PubMed
  19. Diabet Med. 2001 Oct;18(10):816-21 - PubMed
  20. J Pharmacol Exp Ther. 1995 Mar;272(3):1011-5 - PubMed
  21. Neurol Sci. 2012 Aug;33(4):875-80 - PubMed
  22. Am J Physiol Renal Physiol. 2001 Mar;280(3):F480-6 - PubMed
  23. Res Commun Mol Pathol Pharmacol. 2005;117-118:5-12 - PubMed
  24. Rev Endocr Metab Disord. 2008 Dec;9(4):301-14 - PubMed
  25. Clin Chim Acta. 1988 Jul 29;175(3):291-5 - PubMed
  26. Curr Pharm Des. 2008;14(10):962-8 - PubMed
  27. Clin Biochem. 2007 Sep;40(13-14):1020-5 - PubMed
  28. Ann Clin Biochem. 1997 Nov;34 ( Pt 6):638-44 - PubMed
  29. Diabetes Care. 2010 Aug;33(8):1805-10 - PubMed
  30. Biochim Biophys Acta. 1987 Jun 22;924(3):408-19 - PubMed
  31. J Clin Lab Anal. 2010;24(1):6-11 - PubMed
  32. Diabetes Metab. 2001 Sep;27(4 Pt 1):496-502 - PubMed
  33. Nutr Metab Cardiovasc Dis. 2007 Dec;17(10):734-40 - PubMed
  34. J Cell Biochem. 2005 Dec 1;96(5):1086-94 - PubMed
  35. Biochem J. 1994 Mar 1;298 ( Pt 2):249-58 - PubMed
  36. Basic Res Cardiol. 1994;89 Suppl 1:59-70 - PubMed
  37. Exp Toxicol Pathol. 2000 May;52(2):149-55 - PubMed
  38. J Biol Chem. 1952 Nov;199(1):91-5 - PubMed
  39. Rheumatol Int. 2007 Feb;27(4):339-44 - PubMed
  40. Diabetes. 1997 Sep;46 Suppl 2:S19-25 - PubMed
  41. Acta Diabetol. 2008 Mar;45(1):41-6 - PubMed
  42. Arterioscler Thromb Vasc Biol. 1999 Nov;19(11):2640-7 - PubMed
  43. Diabetes Care. 1999 Nov;22(11):1802-7 - PubMed
  44. Nephron. 1983;35(1):58-61 - PubMed
  45. Diabetologia. 2004 Oct;47(10):1727-34 - PubMed
  46. Clin Chim Acta. 1982 Oct 27;125(2):193-205 - PubMed
  47. Tokai J Exp Clin Med. 1996 Dec;21(4-6):207-13 - PubMed
  48. Clin Biochem. 2002 Jun;35(4):263-8 - PubMed
  49. Carcinogenesis. 2002 Dec;23(12):2119-22 - PubMed
  50. Heart Fail Rev. 2004 Jan;9(1):53-61 - PubMed
  51. Acta Neuropathol. 2000 May;99(5):539-46 - PubMed
  52. Cell Mol Biol Lett. 2004;9(4A):643-50 - PubMed

Substances

MeSH terms

Publication Types